179 related articles for article (PubMed ID: 37122702)
21. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
[TBL] [Abstract][Full Text] [Related]
22. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
23. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.
Deng Q; Han G; Puebla-Osorio N; Ma MCJ; Strati P; Chasen B; Dai E; Dang M; Jain N; Yang H; Wang Y; Zhang S; Wang R; Chen R; Showell J; Ghosh S; Patchva S; Zhang Q; Sun R; Hagemeister F; Fayad L; Samaniego F; Lee HC; Nastoupil LJ; Fowler N; Eric Davis R; Westin J; Neelapu SS; Wang L; Green MR
Nat Med; 2020 Dec; 26(12):1878-1887. PubMed ID: 33020644
[TBL] [Abstract][Full Text] [Related]
25. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.
Odak I; Bayir LM; Riemann L; Sikora R; Schneider J; Xiao Y; Möhn N; Skripuletz T; Beutel G; Eder M; Ganser A; Förster R; Schultze-Florey CR; Koenecke C
Front Immunol; 2024; 15():1298598. PubMed ID: 38318174
[TBL] [Abstract][Full Text] [Related]
26. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
27. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA; Martus P; Schmitt M; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner-Drouet EM; Wulf GG; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Fante MA; Schroers R; Bayir L; Borchmann P; Buecklein V; Hasenkamp J; Hanoun C; Thomas S; Beelen DW; Lengerke C; Kroeger N; Dreger P
Blood; 2022 Jul; 140(4):349-358. PubMed ID: 35316325
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
29. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler N; Perbost R; Locke FL; Jain MD; Turcan S; Danan C; Chang EC; Neelapu SS; Miklos DB; Jacobson CA; Lekakis LJ; Lin Y; Ghobadi A; Kim JJ; Chou J; Plaks V; Wang Z; Xue A; Mattie M; Rossi JM; Bot A; Galon J
Nat Med; 2022 Sep; 28(9):1872-1882. PubMed ID: 36038629
[TBL] [Abstract][Full Text] [Related]
30. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
[TBL] [Abstract][Full Text] [Related]
31. A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel.
Baras A; Bocket L; Beauvais D; Hallaert C; Varlet P; Yakoub-Agha I; Hober D; Alidjinou EK
J Mol Diagn; 2021 Apr; 23(4):447-454. PubMed ID: 33385585
[TBL] [Abstract][Full Text] [Related]
32. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
33. Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.
Mika T; Maghnouj A; Klein-Scory S; Ladigan-Badura S; Baraniskin A; Thomson J; Hasenkamp J; Hahn SA; Wulf G; Schroers R
Front Mol Biosci; 2020; 7():84. PubMed ID: 32500079
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
35. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients.
de la Iglesia-San Sebastián I; Carbonell D; Bastos-Oreiro M; Pérez-Corral A; Bailén R; Chicano M; Muñiz P; Monsalvo S; Escudero-Fernández A; Oarbeascoa G; Fernández-Caldas P; Gómez-Centurión I; Pion M; Gayoso J; Anguita J; Kwon M; Díez-Martín JL; Buño I; Martínez-Laperche C
Transplant Cell Ther; 2024 Mar; 30(3):306.e1-306.e12. PubMed ID: 38184148
[TBL] [Abstract][Full Text] [Related]
36. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
[TBL] [Abstract][Full Text] [Related]
37. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
[TBL] [Abstract][Full Text] [Related]
38. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
39. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
40. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
